Hemoglobinopathies Market Growth, Demand and Challenges of the Key Industry Players 2028

1
Global Hemoglobinopathies Market Research and
Forecast Report 2023-2028




Author Elena Anderson, Marketing Manager
IMARC Group
Copyright IMARC Service Pvt Ltd. All Rights
Reserved
2019 IMARC All Rights Reserved
2
About IMARC Group
Report Description
The International Market Analysis Research and
Consulting Group is a leading adviser on
management strategy and market research
worldwide. We partner with clients in all sectors
and regions to identify their highest-value
opportunities, address their most critical
challenges, and transform their
businesses. IMARCs information products include
major market, scientific, economic and
technological developments for business leaders
in pharmaceutical, industrial, and high
technology organizations. Market forecasts and
industry analysis for biotechnology, advanced
materials, chemicals, food and beverage, travel
and tourism, nanotechnology and novel processing
methods are at the top of the companys
expertise. IMARCs tailored approach combines
unfathomable insight into the dynamics of
companies and markets with close cooperation at
all levels of the client organization. This
ensures that our clients achieve unmatchable
competitive advantage, build more proficient
organizations, and secure lasting results.
3
Report Description and Highlights
Report Description
Global Hemoglobinopathies Market Research
Report The latest report by IMARC, titled
Hemoglobinopathies Market Global Industry
Trends, Share, Size, Growth, Opportunity and
Forecast 2023-2028 the global hemoglobinopathies
market size reached US 9.2 Billion in 2022.
Hemoglobinopathies are genetic disorders that
cause abnormalities in the structure and
production of hemoglobin molecules and are passed
from parents to children. These disorders result
from differences in the structure and synthesis
of hemoglobin, which include a variety of
congenital blood ailments. As a result, one of
the globin chains of the hemoglobin molecule
develops an abnormal structure, preventing it
from carrying oxygen through the body and
resulting in anemia. The most common symptoms
of hemoglobinopathies are pale skin, shortness of
breath, cold hands or feet, fatigue, pain and
swelling. This disease is associated with
numerous health problems, such as blurry vision,
heart problems, slowed growth, gallstones,
enlargement of the spleen, and strokes. Request
Free Sample Report https//www.imarcgroup.com/hem
oglobinopathies-market/requestsample
4
Report Description and Highlights
Report Description

Global Hemoglobinopathies Market Trends The
global market is majorly driven by the rising
prevalence of various chronic blood disorders,
including sickle cell disease (SCD) and
thalassemia and anemia. This can be attributed to
the growing geriatric population that is prone to
developing various chronic illnesses. In addition
to this, the widespread adoption of
cost-effective genetic testing, usage of gene
therapy and the approval of novel therapies are
also creating a positive market outlook. The
market is further impelled by partnerships and
collaborations among major biopharmaceutical
players using the latest technology platforms.
Apart from this, multiple favorable
initiatives, including thalassemia screening in
neonates and improved reimbursement scenarios for
diagnostic tests and treatments, undertaken by
the governments of several countries are
impacting the market positively. Some of the
other factors contributing to the market include
continual developments in point-of-care
diagnostics, a considerable rise in medical
expenditure and extensive research and
development (RD) activities. On account of the
aforementioned factors, the market is anticipated
to reach a value of US 16.3 Billion by 2028,
exhibiting a CAGR of 9.39 during
2023-2028. Looking forward, the market value is
projected to reach a strong growth during the
forecast period (2023-2028).
5
Report Description and Highlights
Report Description
Market Summary Breakup by Type Thala
ssemia Alpha Thalassemia
Beta Thalassemia Sickle Cell
Disease Others Breakup by Treatment
Blood Transfusion Stem-cell Tran
splantation Analgesics Antibio
tics ACE Inhibitors Hydroxyure
a Others Breakup by Test Type

6
Report Description and Highlights
Report Description
Red Blood Cell (RBC) Count
Genetic Testing High Performan
ce Liquid Chromatography (HPLC)
Hemoglobin Isoelectric Focusing (Hb
IEF) Hemoglobin Electrophoresis (Hb ELP)
Hemoglobin Solubility Test Breakup by
End User Hospitals and Clinics
Diagnostics Laboratories Others Break
up by Region North America
United States Canada
Asia-Pacific China
Japan India

7
Report Description and Highlights
Report Description
South Korea Au
stralia Indonesia
Others Europe Germ
any France Uni
ted Kingdom Italy
Spain Russia
Others Latin America
Brazil Mexico
Others Middle East and Africa

8
Report Description and Highlights
Report Description

• Competitive Landscape with Key Players
• Bio-Rad Laboratories Inc
• bluebird bio Inc. Bristol-Myers Squibb Company Da
  naher Corporation Emmaus Life Sciences Inc. Gamida
  -Cell Ltd. Global Blood Therapeutics Inc. Novartis
  AG PerkinElmer Inc. Pfizer Inc. Prolong Pharmaceu
  ticals LLC Sangamo Therapeutics Inc. Sysmex Corpor
  ation.
• View Full Report with TOC List of Figure
  https//www.imarcgroup.com/hemoglobinopathies-mark
  et

9
Partial List of Clients
We are the trusted business partners to the
world's leading corporates, governments, and
institutions
A partial List of our Clients
10
Partial List of Clients
We are the trusted business partners to the
world's leading corporates, governments, and
institutions
A partial List of our Clients
11
Report Description and Highlights
Report Description

2019 IMARC All Rights Reserved This
Publication and all its contents unless
otherwise mentioned are copyrighted in the name
of International Market Analysis Research and
Consulting (IMARC). No part of this publication
may be reproduced, repackaged, redistributed or
resold in whole or in any part. The publication
may also not be used in any form or by and means
graphic electronic or mechanical, including
photocopying, recording, taping or by information
storage or retrieval, or by any other form,
without the express consent of International
Market Analysis Research and Consulting
(IMARC). Disclaimer All contents and data of
this publication, including forecasts, data
analysis and opinion have been based on
information and sources believed to be accurate
and reliable at the time of publishing.
International Market Analysis Research and
Consulting makes no representation of warranty of
any kind as to the accuracy or completeness of
any Information provided. IMARC accepts no
liability whatsoever for any loss or damage
resulting from opinion, errors or inaccuracies if
any found this publication. IMARC, IMARC Group
and Global Therapy Insight Series are registered
trademarks of International Market Analysis
Research and Consulting. All other trademarks
used in this publication are registered
trademarks of their respective companies.
12

Contact Us